ASCO 2017 - Lung Cancer - Keytruda is Now Approved in Combination with Chemo for Advanced Non-Squamous NSCLC

Article and Video CATEGORIES

Cancer Journey

ABOUT

Howard Jack West, MD, Founder, Board President

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

Lung Cancer - Keytruda is Now Approved in Combination with Chemo for Advanced Non-Squamous NSCLC

Anonymous

Thu, 08/17/2017 - 08:00

Author

Howard (Jack) West, MD

Drs. H. Jack West, Medical Director of the Thoracic Oncology Program at Swedish Cancer Institute in Seattle, Washington and President and CEO of GRACE, Matthew Gubens, Thoracic Oncologist at the Thoracic Surgery and Oncology Clinic of the UCSF Helen Diller Family Comprehensive Center in San Francisco, California, and Jyoti Patel, Director of Thoracic Oncology at University of Chicago Medicine gathered post meeting to discuss new information from ASCO 2017 regarding lung cancer. In this roundtable video, the doctors discuss Keytruda is Now Approved in Combination with Chemo for Advanced Non-Squamous NSCLC.

Please feel free to offer comments and raise questions in our Discussion Forums.

GRACE would like to thank the following sponsors for their support of this program

Next Previous link

Previous Post Next Post

Article

The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.